Genetically Modified Organisms: A Christian Appeal for Using Biotechnology to Combat World Hunger – Video


Genetically Modified Organisms: A Christian Appeal for Using Biotechnology to Combat World Hunger
Dr. Peter Raven, PhD, President Emeritus of the Missouri Botanical Gardens, presents Genetically Modified Organisms: A Christian Appeal for Using Biotechnology to Combat World Hunger...

By: Washington University Catholic Student Center

Read more here:
Genetically Modified Organisms: A Christian Appeal for Using Biotechnology to Combat World Hunger - Video

Class 12,Biology,Lec-4,Genomic Library,Probe and Genome(Biotechnology)-New – Video


Class 12,Biology,Lec-4,Genomic Library,Probe and Genome(Biotechnology)-New
Class 12,Biology,Genomic Library,Probe and Genome(Biotechnology)-English-Hindi Mix Covers introduction and all the steps of Polymerase Chain Reaction CBSE Class XI,Class XII,Physics ...

By: sci4you

Continued here:
Class 12,Biology,Lec-4,Genomic Library,Probe and Genome(Biotechnology)-New - Video

(Yikes!) MY BLOOD WORK On Testosterone Replacemen Therapy (Part 2 of 2) | feat. Dr. Erica Zelfand – Video


(Yikes!) MY BLOOD WORK On Testosterone Replacemen Therapy (Part 2 of 2) | feat. Dr. Erica Zelfand
MY BLOOD WORK ON TRT FROM 1 YEAR AGO: https://www.youtube.com/watch?v=EkSYEuSVT1Q Time to Examine my hormones! My current dosage on Testosterone Replacement Therapy is ...

By: bignoknow

View post:
(Yikes!) MY BLOOD WORK On Testosterone Replacemen Therapy (Part 2 of 2) | feat. Dr. Erica Zelfand - Video

Weight Loss Experience Interview with Yamily Benigni – Video


Weight Loss Experience Interview with Yamily Benigni
Check out Yamily #39;s blog in Portuguese: http://www.emagrecercerto.com And her youtube channel with loads of yum recipes in Portuguese: http://www.youtube.com/emagrecercerto Yamily is a Tastemade Network ...

By: Healthy Lifestyle Recipes

Here is the original post:
Weight Loss Experience Interview with Yamily Benigni - Video

New autism-causing genetic variant identified

Using a novel approach that homes in on rare families severely affected by autism, a Johns Hopkins-led team of researchers has identified a new genetic cause of the disease. The rare genetic variant offers important insights into the root causes of autism, the researchers say. And, they suggest, their unconventional method can be used to identify other genetic causes of autism and other complex genetic conditions.

A report on the study appears in the April 2 issue of the journal Nature.

In recent years, falling costs for genetic testing, together with powerful new means of storing and analyzing massive amounts of data, have ushered in the era of the genomewide association and sequencing studies. These studies typically compare genetic sequencing data from thousands of people with and without a given disease to map the locations of genetic variants that contribute to the disease. While genomewide association studies have linked many genes to particular diseases, their results have so far failed to lead to predictive genetic tests for common conditions, such as Alzheimer's, autism or schizophrenia.

"In genetics, we all believe that you have to sequence endlessly before you can find anything," says Aravinda Chakravarti, Ph.D. , a professor in the Johns Hopkins University School of Medicine's McKusick-Nathans Institute of Genetic Medicine. "I think whom you sequence is as important -- if not more so -- than how many people are sequenced."

With that idea, Chakravarti and his collaborators identified families in which more than one female has autism spectrum disorder, a condition first described at Johns Hopkins in 1943. For reasons that are not understood, girls are far less likely than boys to have autism, but when girls do have the condition, their symptoms tend to be severe. Chakravarti reasoned that females with autism, particularly those with a close female relative who is also affected, must carry very potent genetic variants for the disease, and he wanted to find out what those were.

The research team compared the gene sequences of autistic members of 13 such families to the gene sequences of people from a public database. They found four potential culprit genes and focused on one, CTNND2, because it fell in a region of the genome known to be associated with another intellectual disability. When they studied the gene's effects in zebrafish, mice and cadaveric human brains, the research group found that the protein it makes affects how many other genes are regulated. The CTNND2 protein was found at far higher levels in fetal brains than in adult brains or other tissues, Chakravarti says, so it likely plays a key role in brain development.

Specifically, mutations in CNNTD2 disrupted the connections called synapses that form among brain cells. "This is consistent with recent findings that many gene mutations associated with autism are involved in synapse development," says Richard Huganir, Ph.D. , director of the Solomon H. Snyder Department of Neuroscience, who participated in the research. "The results of this study add to the evidence that abnormal synaptic function may underlie the cognitive defects in autism."

While autism-causing variants in CTNND2 are very rare, Chakravarti says, the finding provides a window into the general biology of autism. "To devise new therapies, we need to have a good understanding of how the disease comes about in the first place," he says. "Genetics is a crucial way of doing that."

Chakravarti's research group is now working to find the functions of the other three genes identified as possibly associated with autism. They plan to use the same principle to look for disease genes in future studies of 100 similar autism-affected families, as well as other illnesses. "We've shown that even for genetically complicated diseases, families that have an extreme presentation are very informative in identifying culprit genes and their functions -- or, as geneticists are taught, 'treasure your exceptions.'" Chakravarti says.

###

Here is the original post:
New autism-causing genetic variant identified

Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models

Contact Information

Available for logged-in reporters only

Newswise Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells. Leading a multidisciplinary group from Dartmouth College, Karl E. Griswold, PhD published, "Antibody-mediated targeting of iron oxide nanoparticles to the Folate receptor alpha increases tumor cell association in vitro and in vivo," in the International Journal of Nanomedicine, which follows closely the publication of "Tumor Cell Targeting by Iron Oxide Nanoparticles is Dominated by Different Factors in Vitro versus in Vivo," published in PLOS ONE.

"The ultimate utility of anti-cancer nanoparticle technologies will depend in large part on their capacity to selectively home to cancer cells," explained Griswold. "Achieving optimal targeting of nanoparticles in clinically relevant scenarios remains a key challenge for researchers in this space."

The in vivo environment is enormously complex, and there exists an extensive array of variables that determine distribution and cellular targeting of nanoparticles in the body. Homing of nanoparticles to tumors is dependent upon parameters such as nanoparticle size and composition, molecular targeting, surface chemistry, route of administration, cancer cell type, and tumor location.

Using carefully designed and rigorously validated functional nanomaterials, the Dartmouth team pursued a systematic study of those variables in xenograft models of both breast and ovarian human cancers. The in vivo studies showed that antibody targeted iron oxide nanoparticles accumulated in tumor tissues following systemic administration, whereas non-targeted nanoparticles failed to show any detectable tumor association. Importantly, molecular targeting not only localized nanoparticles to tumor masses, but it also resulted in nanoparticle internalization by the cancer cells at a microscopic level.

"This ability to accumulate iron oxide nanoparticles within cancerous cells following systemic administration has important implications for diagnostic and therapeutic applications of this particular type of magnetic nanomaterial," said Griswold.

The multidisciplinary Dartmouth studies utilized a broad variety of Dartmouth's Shared Resources for scientific investigation including the Dartmouth Transgenic and Genetic Construct Shared Resource; the Dartmouth Electron Microscope Facility; the Dartmouth Center for Cancer Nanotechnology Excellence, Toxicology, Biodistribution, and Pathology Core; the Dartmouth Trace Element Core; and the Dartmouth-Hitchcock Norris Cotton Cancer Center Pathology Translational Research Core. All of the Dartmouth Cores and Shared Resources are open to outside investigators by arrangement.

"In studying cancer at Dartmouth, we are committed to team science," said Griswold. "Solutions to problems like these require transdisciplinary collaborations operating at the complex interfaces between molecular biotechnology, nanotechnology, biology, and medicine."

Looking forward, the researchers are in the final stages of follow-up work synthesizing and characterizing more sophisticated iron oxide nanoparticles that are more capable of targeting the inherent heterogeneity of cell surface markers in tumor microenvironments.

See more here:
Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models